{
    "clinical_study": {
        "@rank": "77515", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of CP4071 in treating patients who have\n      locally advanced or metastatic soft tissue sarcoma."
        }, 
        "brief_title": "CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma", 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy, in terms of response rate, of CP4071 in patients with\n           previously treated, locally advanced or metastatic soft tissue sarcoma.\n\n        -  Determine the clinical toxic effects of this drug in these patients.\n\n      OUTLINE: Patients receive oral CP4071 daily. Treatment continues in the absence of disease\n      progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed soft tissue sarcoma\n\n               -  Metastatic or locally advanced\n\n               -  Failed at least 1 prior therapy\n\n          -  Measurable disease outside prior irradiation field\n\n          -  No CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  SWOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine less than 1.5 times ULN\n\n          -  Calcium less than ULN\n\n          -  Potassium normal\n\n        Other:\n\n          -  No other malignancy within the past 5 years except stage I or II cancer in complete\n             remission, carcinoma in situ of the cervix, or basal cell or squamous cell skin\n             cancer\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior biologic response modifier therapy allowed\n\n        Chemotherapy:\n\n          -  No more than 3 prior chemotherapy regimens for advanced, recurrent, or metastatic\n             disease\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy for malignancy\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  At least 4 weeks since prior surgery and recovered\n\n        Other:\n\n          -  No other concurrent cardiac glycosides"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00017446", 
            "org_study_id": "CDR0000068689", 
            "secondary_id": [
                "CPMC-IRB-9825", 
                "NCI-G01-1952"
            ]
        }, 
        "intervention": {
            "intervention_name": "CP4071", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Digitoxin"
        }, 
        "keyword": [
            "stage III adult soft tissue sarcoma", 
            "recurrent adult soft tissue sarcoma", 
            "stage IV adult soft tissue sarcoma"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CPMC-IRB-9825"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Herbert Irving Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas", 
        "overall_official": {
            "affiliation": "Herbert Irving Comprehensive Cancer Center", 
            "last_name": "Robert N. Taub, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00017446"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Herbert Irving Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2002"
    }, 
    "geocoordinates": {
        "Herbert Irving Comprehensive Cancer Center": "40.714 -74.006"
    }
}